NICOX ANNOUNCES PFIZER'S EXERCISE OF OPTION TO DEVELOP LEAD COMPOUND FROM OPHTHALMOLOGY COLLABORATION

NicOx S.A. (Eurolist: NICOX) today announced that Pfizer Inc. has selected a development candidate in its collaboration with NicOx, which is focused on novel nitric oxide-donating compounds in ophthalmology. Accordingly, Pfizer has exercised its option to acquire an exclusive worldwide license to the proprietary NicOx compounds covered by the agreement. NicOx will receive a euro 2M payment from Pfizer.

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=353091)